Singapore markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.06-0.16 (-1.57%)
As of 01:39PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.39B
Enterprise value 361.84M
Trailing P/E 5.92
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)31.27
Price/book (mrq)0.90
Enterprise value/revenue 8.23
Enterprise value/EBITDA 0.90

Trading information

Stock price history

Beta (5Y monthly) 0.48
52-week change 3-28.78%
S&P500 52-week change 322.23%
52-week high 314.45
52-week low 37.61
50-day moving average 39.84
200-day moving average 39.60

Share statistics

Avg vol (3-month) 31.19M
Avg vol (10-day) 3993.91k
Shares outstanding 5136.06M
Implied shares outstanding 6136.06M
Float 890.93M
% held by insiders 111.49%
% held by institutions 176.11%
Shares short (28 Jun 2024) 44.76M
Short ratio (28 Jun 2024) 42.93
Short % of float (28 Jun 2024) 45.72%
Short % of shares outstanding (28 Jun 2024) 43.50%
Shares short (prior month 31 May 2024) 46.02M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-142.05%

Management effectiveness

Return on assets (ttm)-16.73%
Return on equity (ttm)-30.67%

Income statement

Revenue (ttm)79.6M
Revenue per share (ttm)0.59
Quarterly revenue growth (yoy)-10.50%
Gross profit (ttm)N/A
EBITDA -578.4M
Net income avi to common (ttm)-539.44M
Diluted EPS (ttm)-4.01
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.15B
Total cash per share (mrq)8.45
Total debt (mrq)121.08M
Total debt/equity (mrq)7.82%
Current ratio (mrq)12.90
Book value per share (mrq)11.39

Cash flow statement

Operating cash flow (ttm)-762.39M
Levered free cash flow (ttm)-612.25M